biweekly irinotecan monotherapy for refractory advanced pancreatic cancer
- Conditions
- advanced pancreatic cancer refractory to chemotherapy
- Registration Number
- JPRN-UMIN000009739
- Lead Sponsor
- The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 53
Not provided
1) Patients with active infection 2) Patients with active GI bleeding 3) Patients with intestinal pneumonia, pulmonary fibrosis, and severe pulmonary emphysema 4) Patients with uncontrolled pleural effusion or ascites 5) Patients with watery diarrhea or ileus 6) Patients with synchronous or metachronous concomitant malignancies 7) Pregnant or lactating female or patients who are considering pregnancy 8) Patients with contraindication to irinotecan 9) Patients who are actively on other anticancer treatment 10) Inappropriate patients for entry on this study in the judgement of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.